A clinical decision tool including a decision tree, point-of-care testing of CRP, and safety-netting advice to guide antibiotic prescribing in acutely ill children in primary care in Belgium (ARON): a pragmatic, cluster-randomised, controlled trial

Further Publications Immunology

Biomarker-Guided Antibiotic Duration for Hospitalized Patients With Suspected Sepsis: The ADAPT-Sepsis Randomized Clinical Trial

JAMA

Dark P, Hossain A, McAuley DF, Brealey D, Carlson G, Clayton JC, Felton TW, Ghuman BK, Gordon AC, Hellyer TP, Lone NI, Manazar U, Richards G, McCullagh IJ, McMullan R, McNamee JJ, McNeil HC, Mouncey PR, Naisbitt MJ, Parker RJ, Poole RL, Rostron AJ, Singer M, Stevenson MD, Walsh TS, Welters ID, Whitehouse T, Whiteley S, Wilson P, Young KK, Perkins GD, Lall R, ADAPT-Sepsis Collaborators

doi: 10.1001/jama.2024.26458

Immune Response

Seven versus 14 days of antimicrobial therapy for severe multidrug-resistant Gram-negative bacterial infections in intensive care unit patients (OPTIMISE): a randomised, open-label, non-inferiority clinical trial

Crit Care

Arns B, Kalil AC, Sorio GGL, Boschi E, Antonio ACP, Antonio JP, Birriel DC, Lanziotti DH, da Cunha Abbott F, Rocha GC, de Fátima Fernandes V, de Souza Dantas VC, da Silva Medeiros GF, de França Diniz Rocha V, Pereira FC, Gobatto ALN, Lima VP, Lacerda FH, de Maio Carrilho CMD, de Oliveira Cardozo KDN, Irineu VM, Kurtz P, Horvath JDC, Sesin GP, Agani CAJO, Dos Santos TM, Brochier LSB, da Rosa BS, Tomazini BM, Besen BAMP, Pereira AJ, Veiga VC, Nascimento GM, Zavascki AP, OPTIMISE Study Group

doi: 10.1186/s13054-024-05178-6

Osteoarthritis

Tailored exercise management versus usual care for people aged 80 years or older with hip/knee osteoarthritis and comorbidities (TEMPO): multicentre feasibility randomised controlled trial in England

BMJ Open

Nicolson PJA, Holden MA, Marian I, Saeedi E, Williamson E, Moylan D, Stone M, Hopewell S, Lamb SE, TEMPO feasibility trial collaborators

doi: 10.1136/bmjopen-2025-104813

Rheumatoid Arthritis

Remote monitoring or patient-initiated care in axial spondyloarthritis: a 3-armed randomised controlled noninferiority trial

Ann Rheum Dis

Berg IJ, Kristianslund EK, Tveter AT, Sexton J, Bakland G, Gossec L, Hakim S, Macfarlane GJ, Moholt E, Provan SA, Thomassen EEK, de Thurah A, Haavardsholm EA, Lillegraven S, Osteras N

doi: 10.1016/j.ard.2025.04.019

Further Publications Dermatology

Evaluation of Health Education Based on Pictograms and Video Sequences in the Prevention of Hand Eczema Among Hospital Cleaners: A Cluster-Randomised Controlled Trial With 24 Weeks Follow-Up

Contact Dermatitis

Sedeh FB, Ullum AG, Christensen KB, Mortensen OS, Michaelsdóttir TE, Stückler SG, Jemec GBE, Ibler KS

doi: 10.1111/cod.14741

Further Publications Immunology

Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine targeting serogroups A, C, W, Y, and X when co-administered with routine childhood vaccines at ages 9 months and 15 months in Mali: a single-centre, double-blind, randomised, controlled, phase 3, non-inferiority trial

Lancet

Diallo F, Haidara FC, Tapia MD, Dominguez Islas CP, Alderson MR, Hausdorff WP, Martellet L, Hosken N, Kapse D, Kulkarni PS, Townsend-Payne K, Vanni F, Posavad CM, Sow SO, Kotloff KL, Chen WH, NmCV-5 EPI study team

doi: 10.1016/S0140-6736(25)00046-7

Allergic Diseases

Pragmatic Removal of Penicillin Allergy Electronic Health Record Labels: The PROPEL Trial A Randomized Clinical Trial

J Allergy Clin Immunol Pract

Stone CA Jr, Prigmore HL, McCoy AB, Stollings JL, Dear ML, Hiser W, Van Winkle G, Kripalani S, Wright A, Harrell FE, Rice TW, Lindsell CJ, Phillips EJ, Vanderbilt Learning Healthcare System Platform Investigators

doi: 10.1016/j.jaip.2025.07.006

Immune Response

Chikungunya virus virus-like particle vaccine safety and immunogenicity in adults older than 65 years: a phase 3, randomised, double-blind, placebo-controlled trial

Lancet

Tindale LC, Richardson JS, Anderson DM, Mendy J, Muhammad S, Loreth T, Tredo SR, Ramanathan R, Jenkins VA, Bedell L, Ajiboye P, EBSI-CV-317-005 Study Group

doi: 10.1016/S0140-6736(25)00372-1

Further Publications Rheumatology

Efficacy and safety of infliximab or adalimumab in severe mucocutaneous Behçet's syndrome refractory to traditional immunosuppressants: a 6-month, multicentre, randomised controlled, prospective, parallel group, single-blind trial